Stockscreener 앱 받기
24.12
0.29%
0.07
시간 외 거래:
24.12
전일 마감가:
$24.05
열려 있는:
$24.8
하루 거래량:
1.28M
Relative Volume:
1.41
시가총액:
$2.01B
수익:
$352.57M
순이익/손실:
$-143.01M
주가수익비율:
-5.3481
EPS:
-4.51
순현금흐름:
$-153.40M
1주 성능:
-20.53%
1개월 성능:
+1.99%
6개월 성능:
-2.03%
1년 성능:
-12.20%
1일 변동 폭
$23.71
$25.05
1주일 범위
$23.62
$30.66
52주 변동 폭
$20.84
$49.50
빔 테라퓨틱스 Stock (BEAM) Company Profile
명칭
Beam Therapeutics Inc
전화
857-327-8775
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
BEAM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| BEAM | 24.12 | 2.01B | 352.57M | -143.01M | -153.40M | -4.51 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
빔 테라퓨틱스 Stock (BEAM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-10-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 개시 | Citigroup | Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-01-05 | 개시 | Guggenheim | Buy |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-09-24 | 재개 | Stifel | Buy |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Redburn | Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 개시 | Wells Fargo | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-08-05 | 개시 | William Blair | Outperform |
| 2020-03-02 | 개시 | Barclays | Overweight |
| 2020-03-02 | 개시 | JP Morgan | Overweight |
| 2020-03-02 | 개시 | Jefferies | Buy |
| 2020-03-02 | 개시 | Wedbush | Outperform |
모두보기
빔 테라퓨틱스 주식(BEAM)의 최신 뉴스
Beam Therapeutics Inc. (NASDAQ:BEAM) Short Interest Up 10.3% in October - MarketBeat
Beam Therapeutics management to meet virtually with Cantor Fitzgerald - Nasdaq
Sumitomo Mitsui Trust Group Inc. Boosts Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics' SWOT analysis: base editing pioneer's stock faces market hurdles - Investing.com Australia
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Sold by Baillie Gifford & Co. - MarketBeat
FMR LLC Bolsters Position in Beam Therapeutics Inc with Recent A - GuruFocus.com
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference - Marketscreener.com
Beam Therapeutics CEO to Present at Jefferies Healthcare Conference in London | BEAM Stock News - StockTitan
Research Analysts Issue Forecasts for BEAM FY2024 Earnings - MarketBeat
Patient With Sickle Cell Disease Dies From Complications Related to Busulfan-Conditioning Following Treatment With Beam’s Base-Editing HSC Therapy BEAM-101 - CGTLive™
Trading (BEAM) With Integrated Risk Controls - Stock Traders Daily
Beam Therapeutics Inc. (NASDAQ:BEAM) President Giuseppe Ciaramella Sells 51,110 Shares - MarketBeat
Beam Therapeutics president sells $1.35 million in stock - Investing.com India
Insider Sale: President Giuseppe Ciaramella Sells Shares of Beam Therapeutics Inc (BEAM) - GuruFocus.com
Beam Therapeutics president sells $1.35 million in stock By Investing.com - Investing.com UK
ARK Investment Management LLC Has $160.01 Million Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
FY2024 EPS Estimate for Beam Therapeutics Lowered by Analyst - MarketBeat
Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch - Seeking Alpha
Beam Therapeutics (NASDAQ:BEAM) Stock Rating Upgraded by Leerink Partnrs - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Given "Buy" Rating at HC Wainwright - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Q3 2024 Earnings Call Transcript - Insider Monkey
Wedbush Expects Reduced Earnings for Beam Therapeutics - MarketBeat
William Blair Cuts Earnings Estimates for Beam Therapeutics - MarketBeat
Beam Therapeutics upgraded to Outperform from Market Perform at Leerink - Yahoo Finance
Leerink Partners Upgrades Beam Therapeutics (BEAM) - MSN
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates - MSN
Beam stock rebounds as Leerink upgrades despite fatality in gene editing trial - MSN
Beam stock rebounds as Leerink upgrades (BEAM:NASDAQ) - Seeking Alpha
Breaking Down Beam Therapeutics: 5 Analysts Share Their Views - Benzinga
This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday - Benzinga
Beam Therapeutics (NASDAQ:BEAM) Raised to "Outperform" at Leerink Partners - MarketBeat
Beam Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: P - GuruFocus.com
Beam points to positive data with key base editing asset - pharmaphorum
Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: Promising BEACON Trial Results ... - Yahoo Finance
Beam Therapeutics Reports Steady Progress in Q3 2024 - TipRanks
Patient Dies in Beam Trial of SCD Candidate; Company Cites Conditioning - Genetic Engineering & Biotechnology News
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates - MSN
Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial - AOL
Beam Is Laser-Focused On ASH As It Reports Promising Sickle Cell Data, And A Death - Citeline News & Insights
SCD phase I/II death shines Beam on ‘very real’ busulfan risk - BioWorld Online
Beam’s Base-Editing Sickle Cell Therapy Shows Early Promise, But a Fatality Overshadows Results - MedCity News
Stifel maintains $69 target on Beam Therapeutics stock By Investing.com - Investing.com Canada
JPMorgan maintains $48 target on Beam Therapeutics stock - Investing.com
Stifel maintains $69 target on Beam Therapeutics stock - Investing.com
Beam’s early base editing clinical data overshadowed by patient death - The Business Journals
Beam Therapeutics to Present Data Across Hematology - GlobeNewswire
Beam Therapeutics (NASDAQ:BEAM) Shares Gap Down After Earnings Miss - MarketBeat
Beam Therapeutics sustains Outperform stock rating on clinical data - Investing.com
Beam Therapeutics (NASDAQ:BEAM) Posts Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Beam Therapeutics sustains Outperform stock rating on clinical data By Investing.com - Investing.com UK
빔 테라퓨틱스 (BEAM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):